AlgaVac

Company Overview

Snapshot

Founded in November 2022, AlgaVac operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its core technology.

Business overview

AlgaVac is an aquaculture biotechnology company specializing in an algae-based oral delivery platform for vaccines and disease treatments. The company utilizes genetically transformed microalgae as a cell-based production and bio-encapsulation system, creating an algal powder that can be mixed into feed for vaccine delivery. This approach aims to reduce reliance on manual injectable vaccination and handling-intensive disease prevention methods in the aquaculture industry. AlgaVac operates within the Health Tech & Life Sciences sector, specifically targeting Pharma & Medical Biotechnology and Drugs Discovery & Development.

Company Intelligence Q&A

What is AlgaVac's primary focus?

AlgaVac is focused on developing microalgae-based oral vaccines for aquaculture, aiming to provide a more efficient and sustainable method for disease prevention in fish and other aquatic species.

When was AlgaVac founded?

AlgaVac was founded in November 2022.

What is AlgaVac's core technology?

AlgaVac's core technology involves using genetically transformed microalgae as a cell-based production and bio-encapsulation system to create an algal powder for oral vaccine delivery.

Which industries does AlgaVac serve?

AlgaVac primarily serves the aquaculture industry, providing solutions for disease treatment and prevention in fish and other aquatic species.

What is AlgaVac's current product development stage?

AlgaVac is currently in the R&D stage, developing its microalgae-based oral vaccine platform.